Home / Treatments / GERD Procedure
GERD Procedure denials: what the review data shows
Independent reviewers have decided 64 published cases where an insurer denied GERD Procedure — and they overturned the insurer 39.1% of the time. A denial for GERD Procedure is a starting position, not a final answer.
Published decisions
64
2001–2026
Overturned
39.1%
25 denials reversed
Conditions behind gerd procedure denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| GERD Reflux Disease | 59 | 39% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 58 | 37.9% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 6 | 50% |
Typical time to a decision
21 days
Most land between 15 and 21 days
Handled as urgent
15.6%
Expedited when a delay would cause harm
Recent direction
Rising
23.5% → 66.7% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/ Case Summary: The enrollee requested coverage for laparoscopic placement of an esophageal sphincter augmentation device (LINX) and cruroplasty. The record indicates the enrollee has gastroesophageal reflux disease and esophagitis. Medications have included ondansetron, famotidine, hycosamine, Dexilant and aluminum magnesium hydroxide. The UGI (upper gastrointestinal series) performed revealed esophageal dysmotility, with increased gastroesophageal junction transit time and a small hiatal hernia without evidence of gastroesophageal reflux. The Bravo pH testing revealed a DeMeester score of 61.5. The findings strongly support a diagnosis of excessive gastroesophageal acid reflux and substantiate an excellent correlation between symptoms of chest pain, regurgitation and reflux of acid.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for magnetic esophageal sphincter augmentation. In this case, the records document the patient’s incomplete response to standard medical therapy, long term symptoms, and incomplete response to proton pump inhibitors (PPIs). Notes reported a history of irritable bowel syndrome since age 18. The patient’s was started on PPI therapy for treatment of primary symptoms of gastroesophageal reflux disease (GERD). The patient had lost 45 pounds over the past few years and her symptoms remained unchanged despite taking omeprazole, Pepcid, and TUMS. The records noted that pH testing showed positive symptom correlation with heartburn, and that high resolution manometry showed normal motility. The patient reported daily reflux. Notes reported continued symptoms refractory to PPI therapy.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for laparoscopic anti-reflux surgery utilizing the LINX Reflux Management System.Findings: Two out of three physician reviewers found that the requested laparoscopic anti-reflux surgery utilizing the LINX Reflux Management System is not likely to be more beneficial than any available standard treatment for the patient’s medical condition.Researchers conducted a controlled clinical trial and concluded that sphincter augmentation with the LINX Reflux Management System provided long-term clinical benefits as demonstrated by reduced esophageal acid exposure, improved GERD-related quality of life, and cessation of dependence on PPIs, with minimal side effects and no safety issues.
A patient has requested authorization and coverage for transoral incisionless fundoplication. The Health Plan has denied this request, indicating that the requested services are investigational for the treatment of the patient’s gastroesophageal reflux disease. A review of the record indicates that the patient has been diagnosed with irritable bowel syndrome, gastroesophageal reflux disease with esophagitis, diaphragmatic hernia without obstruction or gangrene, alcohol abuse, and other lactose intolerance. Abdominal ultrasound revealed no acute process. A distal esophageal biopsy was performed. The pathology report noted mild chronic esophagitis with features suggesting reflux. The results were negative for intestinal metaplasia, dysplasia or malignancy.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for GERD Procedurewhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.